Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

nded periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single minipump placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Hovione today ... has successfully passed a pre-approval inspection by the ... carried out by the FDA Consumer Safety Officer, Ms. ... on 21 st July and concluded on the 25 ... with the principles and guidelines of Good Manufacturing Practices (GMP) ...
(Date:7/31/2014)... VIENNA , July 31, 2014 ... New York results of AFF008, a ... disease. PD01A is the first therapy against the protein alpha-synuclein, ... The Michael J. Fox Foundation for Parkinson,s Research (MJFF) ... presented at the press conference on the impact a disease-modifying ...
(Date:7/31/2014)... -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused ... call on Thursday, August 14, 2014, at 4:30 p.m. Eastern ... 30, 2014. Financial results will be issued in a press ... and CEO James LaFrance will host the call, ... Thursday, August 14, 2014 Time: 4:30 p.m. Eastern time (3:30 ...
Breaking Medicine Technology:Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... BOSTON, Sept. 13 Cardiovascular disease,kills more women ... is gaining more recognition among physicians and patients, ... make diagnosis and,prognosis of women with heart disease ... What is the Optimal Method of Ischemia,Evaluation in ...
... Bionovo, Inc.,(Nasdaq: BNVI ) today announced ... for,the American Society for Pharmacology and Experimental Therapeutics, ... of,Liquiritigenin, a Bioactive Compound Isolated from the Chinese ... one of the active compounds of MF101, Bionovo,s ...
Cached Medicine Technology:What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 2Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate 3
(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 United ... at 9 a.m. on Monday, September 15, with its ... Methodist Church, 3440 Shroyer Rd., Kettering, OH. Dr. ... Counseling in the Emma Toussant Chair will speak on ... , Dr. Justes’ teaching and research interests include pastoral ...
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... Hook Your Ex, a system created by Steve Pratt, who discovered ... their partner, to the point of starvation, that they come back ... taught to hundreds of men and women across the country with ... , Shane Michaels agrees this simple trick is genius and can ... chance at getting back together with their ex. “I was ...
(Date:7/31/2014)... NEWwoodworks, fine woodworking group at New Energy ... a website dedicated to highlighting their craft and their ... handcrafted cabinetry, furniture, stairs , doors, and other ... for taking on the remarkable, challenging projects that few ... reclaimed wood, often using near extinct species such as ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... scientific meetings, “I love the experience of traveling and ... our centers in Southern California. We are now ... few years ago. It is our pleasure to communicate ... presentation about more efficient ways of performing FUE transplantation ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary to Open 144th Year 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 2Health News:NEWwoodworks Fine Woodworking Group Launches New Website 3Health News:Los Angles Hair Transplant Surgeon, Dr. Parsa Mohebi Inspires Doctors at Global Conferences to Adopt His Novel Method in FUE Hair Transplantation 2
... Mich. - A cancer diagnosis affects more than just the ... Michigan Comprehensive Cancer Center finds spouses report similar physical and ... study found that what really impacted emotional distress - among ... was newly diagnosed, facing a recurrence or living with advanced ...
... Board established; Former URAC CEO joins company along with ... Chief Medical Officer, ... of key senior management leaders to head the,growing healthcare consulting and technology ... and CEO; -- Joel V. Brill, MD, AGAF FASGE FACG ...
... research that aligns patients and treatments., ... The,H. Lee Moffitt Cancer Center & ... health enterprise platform, to aid in its,development ... be used,to assimilate large quantities of diverse ...
... MEDIA, Pa., Sept. 20 Synova Healthcare Group,Inc. (OTC ... sale,of approximately $3.3 million in aggregate notional principal amount ... September 19, 2012,and related common stock purchase warrants. This ... private placement of notes and warrants in the,aggregate notional ...
... 2007 Breihan Bridgewater suffers from emphysema. He sleeps on ... it feels like theres a boulder resting on his chest. ... prostate cancer, the thought of undergoing surgery or having to ... treatments left him with an uneasy feeling and a ...
... is leading cause of inherited mental retardation , , THURSDAY, ... defect might be a target for the treatment of ... researchers report. , The discovery in rats provides an ... condition changes the way brain cells communicate, according to ...
Cached Medicine News:Health News:Cancer patients, spouses report similar emotional distress, U-M study finds 2Health News:Schooner Healthcare Services, LLC Announces New Leadership Team 2Health News:Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Radiation therapy technique reduces length of prostate cancer treatment 2Health News:Radiation therapy technique reduces length of prostate cancer treatment 3Health News:Brain Defect Helps Drive Fragile X Syndrome 2Health News:Brain Defect Helps Drive Fragile X Syndrome 3
...
...
... Corneal biomechanical properties influence the results ... procedures, and may hold clues to ... now, assessing the biomechanical properties of ... confining practitioners and researchers to measuring ...
Inquire...
Medicine Products: